KR20190060007A - 덱스메데토미딘 경피 전달 장치를 이용한 통증을 관리하는 방법 - Google Patents

덱스메데토미딘 경피 전달 장치를 이용한 통증을 관리하는 방법 Download PDF

Info

Publication number
KR20190060007A
KR20190060007A KR1020197014883A KR20197014883A KR20190060007A KR 20190060007 A KR20190060007 A KR 20190060007A KR 1020197014883 A KR1020197014883 A KR 1020197014883A KR 20197014883 A KR20197014883 A KR 20197014883A KR 20190060007 A KR20190060007 A KR 20190060007A
Authority
KR
South Korea
Prior art keywords
subject
dexmedetomidine
hours
delivery device
transdermal delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197014883A
Other languages
English (en)
Korean (ko)
Inventor
로즈 마리 곤살베스
주타로 슈도
주타로 슈도
완-닝 송
스티븐 쉬핑 황
Original Assignee
테이코쿠 팔마 유에스에이, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 테이코쿠 팔마 유에스에이, 인코포레이티드 filed Critical 테이코쿠 팔마 유에스에이, 인코포레이티드
Priority to KR1020217028734A priority Critical patent/KR20210113439A/ko
Publication of KR20190060007A publication Critical patent/KR20190060007A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197014883A 2016-10-31 2017-10-31 덱스메데토미딘 경피 전달 장치를 이용한 통증을 관리하는 방법 Ceased KR20190060007A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217028734A KR20210113439A (ko) 2016-10-31 2017-10-31 덱스메데토미딘 경피 전달 장치를 이용한 통증을 관리하는 방법

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662415248P 2016-10-31 2016-10-31
US62/415,248 2016-10-31
US201762547582P 2017-08-18 2017-08-18
US62/547,582 2017-08-18
PCT/US2017/059357 WO2018081812A2 (en) 2016-10-31 2017-10-31 Methods of managing pain using dexmedetomidine transdermal delivery devices

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217028734A Division KR20210113439A (ko) 2016-10-31 2017-10-31 덱스메데토미딘 경피 전달 장치를 이용한 통증을 관리하는 방법

Publications (1)

Publication Number Publication Date
KR20190060007A true KR20190060007A (ko) 2019-05-31

Family

ID=62020311

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020197014883A Ceased KR20190060007A (ko) 2016-10-31 2017-10-31 덱스메데토미딘 경피 전달 장치를 이용한 통증을 관리하는 방법
KR1020237010276A Ceased KR20230048156A (ko) 2016-10-31 2017-10-31 덱스메데토미딘 경피 전달 장치를 이용한 통증을 관리하는 방법
KR1020257021141A Pending KR20250105683A (ko) 2016-10-31 2017-10-31 덱스메데토미딘 경피 전달 장치를 이용한 통증을 관리하는 방법
KR1020217028734A Ceased KR20210113439A (ko) 2016-10-31 2017-10-31 덱스메데토미딘 경피 전달 장치를 이용한 통증을 관리하는 방법

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020237010276A Ceased KR20230048156A (ko) 2016-10-31 2017-10-31 덱스메데토미딘 경피 전달 장치를 이용한 통증을 관리하는 방법
KR1020257021141A Pending KR20250105683A (ko) 2016-10-31 2017-10-31 덱스메데토미딘 경피 전달 장치를 이용한 통증을 관리하는 방법
KR1020217028734A Ceased KR20210113439A (ko) 2016-10-31 2017-10-31 덱스메데토미딘 경피 전달 장치를 이용한 통증을 관리하는 방법

Country Status (10)

Country Link
US (1) US12527770B2 (https=)
EP (1) EP3532038A4 (https=)
JP (3) JP2019534288A (https=)
KR (4) KR20190060007A (https=)
CN (2) CN121868263A (https=)
BR (1) BR112019006955A2 (https=)
CA (1) CA3038354C (https=)
RU (1) RU2723761C1 (https=)
TW (1) TWI764951B (https=)
WO (1) WO2018081812A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI764951B (zh) * 2016-10-31 2022-05-21 美商帝國製藥美國股份有限公司 用於處理疼痛之右美托咪啶經皮遞送裝置
ES2769286T3 (es) 2016-12-20 2020-06-25 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina
WO2018115010A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
KR102793584B1 (ko) 2016-12-31 2025-04-09 바이오엑셀 테라퓨틱스 인코포레이티드 불안의 치료를 위한 설하 덱스메데토미딘의 용도
CN112533593A (zh) * 2018-06-20 2021-03-19 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
PL3813802T3 (pl) 2018-06-27 2025-04-22 Bioxcel Therapeutics, Inc. Formulacje błony zawierające deksmedetomidynę i sposoby ich wytwarzania
US20220241218A1 (en) * 2019-04-17 2022-08-04 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system
EP3999058A4 (en) 2019-07-19 2023-05-03 Bioxcel Therapeutics, Inc. NON-SEDATIVE DEXMEDETOMIDINE-BASED TREATMENT REGIMEN
WO2021026377A1 (en) * 2019-08-07 2021-02-11 Alkermes, Inc. Lactam-containing compounds for the treatment of pain
WO2021026380A1 (en) * 2019-08-07 2021-02-11 Alkermes, Inc. Phenyltriazole compounds for the treatment of pain
WO2021026375A1 (en) * 2019-08-07 2021-02-11 Alkermes, Inc. Fused bicyclic compounds for the treatment of pain
WO2021026378A1 (en) * 2019-08-07 2021-02-11 Alkermes, Inc. Indole compounds for the treatment of pain
CN111281850A (zh) * 2020-03-14 2020-06-16 周琛 止痛药物组合物及其用途
CN116098876A (zh) * 2021-11-11 2023-05-12 北京泰德制药股份有限公司 一种右美托咪定透皮贴剂及其制备方法和应用
WO2024037545A1 (zh) * 2022-08-17 2024-02-22 宜昌人福药业有限责任公司 右美托咪定经皮组合物、透皮贴剂及其制备方法和应用
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
TW202519210A (zh) * 2023-09-05 2025-05-16 美商帝國製藥美國有限公司 用於治療疼痛之經皮遞送貼片

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2101114B (en) 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
JPS60163811A (ja) 1984-02-06 1985-08-26 Watanabe Yakuhin Kogyo Kk プロプラノロ−ル含有外用貼付剤
FI844786A0 (fi) 1984-12-04 1984-12-04 Farmos Oy Terapeutiskt utnyttjbar foerening.
FI864570A0 (fi) 1986-11-11 1986-11-11 Farmos Oy Terapeutiskt anvaendbar foerening.
GB2206880B (en) 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
GB2215206B (en) 1988-02-29 1991-07-03 Farmos Oy 4-substituted imidazole derivatives useful in perioperative care
US4994267A (en) 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5217718A (en) 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5124157A (en) 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
FI894911A0 (fi) 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
US5304569A (en) 1989-11-13 1994-04-19 Orion-Yhtyma Oy Compositions and their use in lowering intraocular pressure
US5447947A (en) 1990-02-26 1995-09-05 Arc 1 Compositions and methods of treatment of sympathetically maintained pain
US5070084A (en) 1990-02-26 1991-12-03 Campbell James N Treatment of sympathetically maintained pain
JP2849937B2 (ja) 1990-04-18 1999-01-27 日東電工株式会社 医療用貼付剤
GB9111732D0 (en) 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
AU2782592A (en) 1991-10-15 1993-05-21 Cygnus Therapeutic Systems Thermal enhancement of transdermal drug administration
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
GB2281206A (en) 1993-08-25 1995-03-01 Orion Yhtymae Oy Use of dexmedetomidine
JPH0776526A (ja) 1993-09-06 1995-03-20 Sansei Seiyaku Kk 乳酸エステルを含有する経皮吸収製剤
JP2819236B2 (ja) 1994-05-06 1998-10-30 日東電工株式会社 経皮吸収製剤
GB2290964A (en) 1994-07-08 1996-01-17 Arto Olavi Urtti Transdermal drug delivery system
WO1996008229A2 (en) 1994-09-14 1996-03-21 Minnesota Mining And Manufacturing Company Matrix for transdermal drug delivery
US5635203A (en) 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
CN1101825C (zh) 1995-03-31 2003-02-19 积水化学工业株式会社 制备溶剂型丙烯酸压敏粘合剂和医用压敏粘合剂的方法
CA2222133C (en) 1995-06-07 2002-12-24 Cygnus, Inc. Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
US5891461A (en) 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
GB9521680D0 (en) 1995-10-23 1996-01-03 Orion Yhtymo Oy New use of imidazole derivatives
US7150881B2 (en) 1997-06-26 2006-12-19 Mylan Technologies, Inc. Adhesive mixture for transdermal delivery of highly plasticizing drugs
IL135258A0 (en) 1997-09-26 2001-05-20 Noven Pharma Bioadhesive compositions and methods for topical administration of active agents
US6329369B1 (en) 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
US20020102291A1 (en) 1997-12-15 2002-08-01 Noven Pharmaceuticals, Inc. Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US20020177592A1 (en) 1998-02-25 2002-11-28 Olney John W. Combination of adrenergic agonist and tricyclo-alkylamine for relieving chronic pain without adverse side effects
US20020068754A1 (en) 1998-02-25 2002-06-06 Olney John W. Combination of adrenergic agonist and aryl-cyclo-alkanolamine for relieving chronic pain without adverse side effects
US20020016319A1 (en) 1998-02-25 2002-02-07 Olney John W. Combined adamantane derivative and adrenergic agonist for relief of chronic pain without adverse side effects
AR015744A1 (es) 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
US7001609B1 (en) 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
NZ510771A (en) 1998-10-02 2003-08-29 3M Innovative Properties Co Mucosal originated drug delivery systems
ES2239466T3 (es) 1998-10-20 2005-09-16 Omeros Corporation Solucion de irrigacion y metodo de inhibicion del dolor y de la inflamacion.
US20030170195A1 (en) 2000-01-10 2003-09-11 Noven Pharmaceuticals, Inc. Compositions and methods for drug delivery
PE20001396A1 (es) 1999-01-18 2000-12-23 Gruenenthal Chemie Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista
DE19918106A1 (de) 1999-04-22 2000-10-26 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit neutralisierten Acrylathaftklebern
GB9913677D0 (en) 1999-06-11 1999-08-11 Imperial College Formulation
DE19938823A1 (de) 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
WO2001047512A2 (en) 1999-12-08 2001-07-05 Fluoro Probe, Inc. Method for relieving pain associated with an internal disease site
AU2001243414B2 (en) 2000-03-10 2005-05-19 Durect Corporation Opioid formulations
AU7576501A (en) 2000-03-28 2001-12-03 John W. Olney Combination of adrenergic agonist and nmda antagonist for relieving chronic painwithout adverse side effects
US20050042194A1 (en) 2000-05-11 2005-02-24 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
EP1155617A1 (en) 2000-05-17 2001-11-21 Rockwool International A/S Mineral wool plant substrate
DE10138722C5 (de) 2000-08-17 2017-05-24 Schaeffler Technologies AG & Co. KG Antriebsstrang
US7635488B2 (en) 2001-03-13 2009-12-22 Dbv Technologies Patches and uses thereof
FR2822049B1 (fr) 2001-03-13 2003-08-01 Dbv Medica 1 Patch destine notamment a depister l'etat de sensibilisation d'un sujet a un allergene, procede de fabrication et utilisation
FR2832311B1 (fr) 2001-11-21 2004-04-16 Besins Int Belgique Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations
AR033748A1 (es) * 2002-05-15 2004-01-07 Thalas Group Inc Un dispositivo para la administracion transdermica de sustancias farmacologicamente activas que comprende dos capas adhesivas superpuestas y un procedimiento para prepararlo
KR100511492B1 (ko) 2002-10-11 2005-08-31 주식회사 태평양 에페리손, 톨페리손 또는 그것들의 염을 포함하는경피흡수제제
US20040209907A1 (en) 2003-01-23 2004-10-21 Richard Franklin Formulation and methods for the treatment of thrombocythemia
DE10305137A1 (de) 2003-02-07 2004-08-26 Novosis Ag Transdermale therapeutische Abgabesysteme mit einem Butenolid
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050059664A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Novel methods for identifying improved, non-sedating alpha-2 agonists
US20050020600A1 (en) 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
JP4694967B2 (ja) 2003-07-31 2011-06-08 久光製薬株式会社 貼付剤
US20050058696A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
MXPA06002716A (es) 2003-09-12 2006-06-06 Allergan Inc Metodos y composiciones para el tratamiento de dolor y otras condiciones mediadas por adrenergicos de alfa-2.
MEP23508A (en) 2003-10-28 2010-06-10 Noven Pharma Compositions and methods for comtrolling drug loss and delivery in transdermal drug delivery systems
JP4955543B2 (ja) 2004-05-25 2012-06-20 サンズローザ ファーマシューティカル ディヴェロップメント インコーポレイテッド 炎症性皮膚疾患を治療又は予防するための化合物、製剤及び方法
CA2580694A1 (en) 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20060166901A1 (en) 2005-01-03 2006-07-27 Yu Ruey J Compositions comprising O-acetylsalicyl derivatives of aminocarbohydrates and amino acids
US8114090B2 (en) 2005-01-06 2012-02-14 Kertzner Richard I Drill centering tool for removal of orthopedic plug
US20060210613A1 (en) 2005-03-15 2006-09-21 Carliss Richard D Therapeutic wound care product
US20070134310A1 (en) 2005-09-23 2007-06-14 Nedberge Diane E Transdermal risperidone delivery system
EP2308480B1 (en) 2005-09-23 2014-08-13 ALZA Corporation High Enhancer-Loading Polyacrylate Formulation for Transdermal Applications
CA2614345C (en) 2005-10-24 2013-01-08 Teikoku Pharma Usa, Inc. Topical pain relief compositions of n,2,3-trimethyl-2-isopropylbutamide and methods for using the same
TWI389709B (zh) 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
CN1994290B (zh) 2006-01-04 2011-03-16 上海医药工业研究院 卡巴拉汀透皮贴剂及其制备方法
CN101395164A (zh) 2006-01-10 2009-03-25 罗伊·J·于 N-(膦酰基烷基)-氨基酸、其衍生物和组合物以及使用方法
WO2007085556A2 (en) 2006-01-27 2007-08-02 F. Hoffmann-La Roche Ag Use of 4-imidazole derivatives for cns disorders
CA2643802A1 (en) 2006-02-27 2007-09-07 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
WO2007103687A2 (en) 2006-03-01 2007-09-13 Tristrata, Inc. Composition and method for topical treatment of tar-responsive dermatological disorders
GB0611241D0 (en) 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production
US20090258063A1 (en) 2006-09-11 2009-10-15 Sekisui Chemical Co., Ltd. Transdermal patch
US20090098191A1 (en) 2007-10-16 2009-04-16 Anderson Christopher G Use of bases to stabilize transdermal formulations
JP5670196B2 (ja) 2007-11-16 2015-02-18 バイセプト セラピューティクス、インク． 紫斑を治療する組成物および方法
US8011146B2 (en) 2007-12-19 2011-09-06 William Krause Blast-proof window and mullion system
WO2009124755A1 (en) 2008-04-08 2009-10-15 European Molecular Biology Laboratory (Embl) Compounds with novel medical uses and method of identifying such compounds
US8629172B2 (en) 2008-04-18 2014-01-14 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising clonidine
JP5547065B2 (ja) 2008-05-15 2014-07-09 久光製薬株式会社 パロノセトロンを含有する経皮吸収製剤
US20110223204A1 (en) 2008-06-04 2011-09-15 Bradford J Duft Treatment of pain with gap junction modulation compounds
WO2010063030A2 (en) 2008-11-30 2010-06-03 Feigelson, Daniel Dermal application of vasoconstrictors
EP2330903A4 (en) 2008-07-28 2011-10-12 Endogenx Inc METHOD FOR TREATING PAIN USING AN ALPHA-2 ADRENEER AGONIST AND AN ENDOTHELINE ANTAGONIST
US20120156244A1 (en) 2008-08-01 2012-06-21 Alpha Synergy Development Inc. Nasal Compositions and Uses Thereof
US20110244058A1 (en) 2008-08-01 2011-10-06 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
US20100197694A1 (en) 2008-08-01 2010-08-05 Gerald Horn Compositions and methods for treatment of diseases and conditions with increased vascular permeability
US20110257188A1 (en) 2008-08-01 2011-10-20 Gerald Horn Compositions and methods for the treatment of nasal conditions
US20100202979A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
EP2165706A1 (en) 2008-09-18 2010-03-24 BioAlliance Pharma Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.
US9308203B2 (en) 2008-10-01 2016-04-12 Taiwan Biotech Co., Ltd. Pressure sensitive adhesive matrix device or system for the treatment or prevention of onychomycosis or tinea pedis
US8603497B2 (en) 2008-10-30 2013-12-10 National University Corporation Okayama University Composition for local anesthesia
US20120095104A1 (en) 2008-11-30 2012-04-19 Oron Zachar Use of vasoconstrictors
US20100196286A1 (en) 2008-12-01 2010-08-05 Armer Thomas A Inhalation delivery methods and devices
FR2942138A1 (fr) 2009-02-16 2010-08-20 Galderma Res & Dev Association de composes pour le traitement ou la prevention des affections dermatologiques
JP2012158521A (ja) 2009-04-17 2012-08-23 Kureha Corp 外用剤
RU2572692C2 (ru) 2009-05-15 2016-01-20 Рекро Фарма, Инк. Сублингвальные композиции дексмедетомидина и способы их применения
US8410140B2 (en) 2009-06-01 2013-04-02 The Regents Of The University Of Michigan Anesthetic methods and compositions
CN102753532B (zh) 2009-12-09 2015-05-13 I-技术有限公司 美托咪定的制备方法
AU2011204315A1 (en) * 2010-01-08 2012-08-02 Recro Pharma, Inc. Topical transdermal dexmedetomidine compositions and methods of use thereof
US9327105B2 (en) 2010-03-26 2016-05-03 Itrace Biomedical Inc. Active transdermal drug delivery system and the method thereof
US20130029989A1 (en) 2010-04-15 2013-01-31 The Royal Institution For The Advancement Of Learning/Mcgill University Topical treatments for pain
US9023788B2 (en) 2010-04-20 2015-05-05 New York University Methods compounds and pharmaceutical compositions for treating anxiety and mood disorders
US8563031B2 (en) 2010-05-27 2013-10-22 Absize, Inc. Piroxicam-containing matrix patches and methods for the topical treatment of acute and chronic pain and inflammation therewith
CN103200944B (zh) 2010-11-17 2016-05-04 赫克萨尔股份公司 包含丁丙诺啡的经皮治疗系统
TWI433904B (zh) 2011-01-12 2014-04-11 Taiwan Biotech Co Ltd 多奈哌齊經皮貼片
US20120202864A1 (en) 2011-02-03 2012-08-09 Alpha Synergy Development Inc. Compositions and Methods for Treatment of Glaucoma
US20120309720A1 (en) 2011-02-03 2012-12-06 Alpha Synergy Development Inc. Compositions and methods for treatment of glaucoma
EP2700401B1 (en) 2011-04-18 2020-01-15 Hisamitsu Pharmaceutical Co., Inc. Method for producing adhesive patch, and adhesive patch
US20130096170A1 (en) * 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
PH12014500785A1 (en) 2011-10-19 2014-05-12 Galderma Sa Method for treating capillary hemangiomas
WO2013072763A2 (en) 2011-11-16 2013-05-23 Nometics Inc. Non-sensitizing transdermal clonidine patch
AU2012352528B9 (en) 2011-12-11 2017-11-02 Baudax Bio, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
US20130211351A1 (en) 2012-01-31 2013-08-15 Gruenenthal Gmbh Pharmaceutical patch for transdermal administration of (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine
WO2013173317A1 (en) 2012-05-14 2013-11-21 Prospire, Llc TREATMENT OF OBSTRUCTIVE SLEEP APNEA WITH α2-ADRENERGIC RECEPTOR AGONISTS
BR112015004643A2 (pt) 2012-08-31 2017-07-04 Univ Midwestern métodos e composições para ressucitação hipotensiva
US20150366821A1 (en) 2012-11-13 2015-12-24 Ucl Business Plc Adrenergic agonists for use in treating liver damage
JP6370802B2 (ja) 2012-12-28 2018-08-08 テイコク ファーマ ユーエスエー インコーポレーテッド 持続性ブプレノルフィン経皮送達組成物およびそれの使用方法
KR101827980B1 (ko) * 2013-10-07 2018-02-13 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법
CA2924233C (en) 2013-10-07 2018-10-23 Teikoku Pharma Usa, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
CA2924190C (en) * 2013-10-07 2019-07-09 Teikoku Pharma Usa, Inc. Methods and compositions for treating withdrawal syndromes using non-sedative dexmedetomidine transdermal compositions
BR112016006848A2 (pt) * 2013-10-07 2017-08-01 Teikoku Pharma Usa Inc métodos e composições para distribuição transdérmica de uma quantidade não sedativa de dexmedetomidina
EP3054931B1 (en) 2013-10-07 2020-12-23 Teikoku Pharma USA, Inc. Transdermal delivery device for managing pain comprising dexmedetomidine transdermal compositions
US9974754B2 (en) 2013-12-18 2018-05-22 Maruishi Pharmaceutical Co., Ltd. Hydrous adhesive patch
WO2016105449A1 (en) 2014-12-22 2016-06-30 Seth Lederman Compounds for use as pain therapeutics
TWI764951B (zh) 2016-10-31 2022-05-21 美商帝國製藥美國股份有限公司 用於處理疼痛之右美托咪啶經皮遞送裝置
TWI772807B (zh) 2019-05-27 2022-08-01 日商救急藥品工業股份有限公司 外用製劑
EP4364729A4 (en) 2021-08-23 2024-11-27 Yichang Humanwell Pharmaceutical Co., Ltd. TRANSDERMAL COMPOSITION OF DEXMEDETOMIDINE, TRANSDERMAL PATCH AND METHOD OF PREPARATION AND USE THEREOF
CN116098876A (zh) 2021-11-11 2023-05-12 北京泰德制药股份有限公司 一种右美托咪定透皮贴剂及其制备方法和应用
TW202519210A (zh) 2023-09-05 2025-05-16 美商帝國製藥美國有限公司 用於治療疼痛之經皮遞送貼片

Also Published As

Publication number Publication date
EP3532038A4 (en) 2020-06-03
JP2019534288A (ja) 2019-11-28
KR20230048156A (ko) 2023-04-10
EP3532038A2 (en) 2019-09-04
KR20210113439A (ko) 2021-09-15
JP2023036825A (ja) 2023-03-14
CA3038354C (en) 2021-08-17
US20180117012A1 (en) 2018-05-03
JP2025108704A (ja) 2025-07-23
CA3038354A1 (en) 2018-05-03
KR20250105683A (ko) 2025-07-08
WO2018081812A2 (en) 2018-05-03
US12527770B2 (en) 2026-01-20
TWI764951B (zh) 2022-05-21
RU2723761C1 (ru) 2020-06-17
BR112019006955A2 (pt) 2019-07-02
WO2018081812A3 (en) 2019-01-17
TW201817419A (zh) 2018-05-16
CN110022865A (zh) 2019-07-16
CN121868263A (zh) 2026-04-17

Similar Documents

Publication Publication Date Title
KR20190060007A (ko) 덱스메데토미딘 경피 전달 장치를 이용한 통증을 관리하는 방법
KR101891186B1 (ko) 덱스메데토미딘 경피 조성물을 포함하는 통증을 관리하기 위한 방법 및 조성물
TWI704933B (zh) 右美托咪啶經皮輸送裝置及使用其之方法
RU2648449C2 (ru) Способы и композиции для трансдермальной доставки неседативного количества дексмедетомидина
KR20180021902A (ko) 비진정성 덱스메데토미딘 경피 조성물을 사용하여 금단 증후군을 치료하기 위한 방법 및 조성물
EA009921B1 (ru) Способ лечения синдрома отвыкания от зависимости у беременных женщин
CA2294950C (en) Levobupivacaine and its use
US20250275930A1 (en) Transdermal delivery patch for treating pain
HK40010492A (en) Methods of managing pain using dexmedetomidine transdermal delivery devices
JP2004525960A (ja) 尿失禁、特に切迫尿失禁の治療用経皮デリバリーディバイスの製造にブプレノルフィンを使用する方法
HK40018815A (en) Methods and compositions for managing pain comprising dexmedetomidine transdermal compositions
BR112016007327B1 (pt) Uso de dispositivo de distribuição transdérmica para controlar dor

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20190523

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
AMND Amendment
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201012

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210428

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20201012

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20210428

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20201130

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20190528

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20210809

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210723

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20210428

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20201130

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20201012

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190528

X601 Decision of rejection after re-examination
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210907